

Resource Summary Report

Generated by PRECISE-TBI on Sep 2, 2026

PE anti-mouse CD137

RRID:AB_2287565

Type: Antibody

Proper Citation

BioLegend Cat# 106106, RRID:AB_2287565

Antibody Information

URL: http://antibodyregistry.org/AB_2287565

Proper Citation: BioLegend Cat# 106106, RRID:AB_2287565

Target Antigen: CD137

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD137

Description: This monoclonal targets CD137

Target Organism: mouse

Clone ID: Clone 17B5

Antibody ID: AB_2287565

Vendor: BioLegend

Catalog Number: 106106

Alternative Catalog Numbers: 106105

Record Creation Time: 20231110T045003+0000

Record Last Update: 20260831T203210+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD137.

No alerts have been found for PE anti-mouse CD137.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

This S, et al. (2024) Machine learning predictions of T cell antigen specificity from intracellular calcium dynamics. Science advances, 10(10), eadk2298.

Pan Y, et al. (2024) Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. Cell reports. Medicine, 5(6), 101590.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. Cell, 187(11), 2690.

Muñoz-Ruiz M, et al. (2023) IFN- γ -dependent interactions between tissue-intrinsic $\gamma\delta$ T cells and tissue-infiltrating CD8 T cells limit allergic contact dermatitis. The Journal of allergy and clinical immunology, 152(6), 1520.

Eschweiler S, et al. (2023) JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. Cell reports, 42(2), 112040.

Cannons JL, et al. (2021) PI3K γ coordinates transcriptional, chromatin, and metabolic changes to promote effector CD8+ T cells at the expense of central memory. Cell reports, 37(2), 109804.

Kim SI, et al. (2021) Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Molecular cancer therapeutics, 20(1), 173.

Ettxeberria I, et al. (2019) Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer cell, 36(6), 613.

Marcus A, et al. (2018) Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response. Immunity, 49(4), 754.